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Aim:Anultrasensitive UPLC–MS/MSassay for liraglutidewas developed and validated according toUS FDA
and EMA guidelines and applied to the quantification of plasma concentrations after intravenous, nasal
and oral administration of liraglutide to beagle dogs. Results: Liraglutide isolation was performed with a
combined protein precipitation and solid-phase extraction protocol. The calibrated concentration range
of 0.1–200 ng/ml was linear with correlation coefficients >0.998. Precise analysis was achieved through
the utilization of an isotopically labeled internal standard. Absolute bioavailability of liraglutide after
nasal and oral administration of liraglutide to beagle dogs was 0.03 and 0.006%, respectively. Conclusion:
The assay matches the performance in sensitivity of the previously applied immunoassay and optimally
covers the therapeutic range of liraglutide.
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Analogs of the endogenous GLP-1 are increasingly utilized and recommended early for the treatment of Type 2
diabetes mellitus [1]. GLP-1 is secreted mainly from L-cells of the gut following food intake and exhibits a half-life
of approximately 2 min because of its rapid degradation by DPP-4 [2]. GLP-1 acts on GLP-1 receptors present
in stomach, pancreas, brain and heart. It stimulates insulin secretion of pancreatic β-cells in the presence of
hyperglycemia, delays gastric emptying, reduces appetite and exhibits positive effects on myocardial function [3].
Liraglutide, which is modified with a fatty acid for increased half-life and like all GLP-1 analogs shows elevated
stability against DPP-4 degradation, is approved for the treatment of Type 2 diabetes mellitus and obesity [4].
Like most peptides, liraglutide has to be administered as subcutaneous injection because of its very low oral
bioavailability. In order to avoid long-term injection therapy, alternative formulations enabling other routes of
administration are desirable. To support development of novel noninjectable formulations of liraglutide, a highly
sensitive and selective quantification assay is required. Traditionally, peptides are quantified using immunoassays
because of the high sensitivity needed for reliable quantification of their usually low plasma concentrations. With
the development of sensitive mass spectrometers, quantification of peptides is increasingly performed by MS/MS
techniques because of their advantages of wider dynamic range, often great accuracy, and especially superior
specificity because of the lack of crossreactivity [5].
Challenges arising in the MS/MS analysis of liraglutide are mainly because of its heavy molecular weight and
numerous peptide bonds. The broad isotopic pattern and multiple charge distribution are lowering signal intensity
of the MS signal while the resulting multitude of fragments in collision-induced decomposition (CID) is strongly
diluting intensity in multiple reaction monitoring (MRM).
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A few MS/MS assays for the quantification of liraglutide in plasma have been reported relying on LC–MS/MS
techniques [6–9]. The lowest LLOQ previously reported is 0.5 ng/ml when using 50 μl of plasma for the quantifi-
cation of liraglutide in rat plasma [9].
To support formulation development including the determination of the bioavailabilities after oral and nasal
administration, we developed an ultrasensitive UPLC–MS/MS assay for the quantification of liraglutide in plasma.
The assay with an LLOQ of 0.1 ng/ml using 100 μl of plasma was fully validated according to US FDA and
EMA pertinent guidelines [10,11]. It was subsequently applied to plasma samples of beagle dogs after oral, nasal and
intravenous administration of liraglutide.
Material & methods
Beagle study & plasma sample generation
For the determination of the bioavailability of liraglutide after oral and nasal administration in beagle dogs, two
studies were performed both conducted at commercial laboratories. The studies were carried out in accordance with
national and European guidelines for the care and use of laboratory animals (European regulations; 2010/63/EU).
The first study was performed at Charles River Laboratories Ltd (Tranent, Edinburgh, UK) under the UK Home
Office Project License number PPL 70/8781. Four animals received an intravenous bolus injection of 0.5 mg
liraglutide in 0.5 ml of phosphate-buffered saline (PBS). After a wash-out period of 2 weeks, the animals received
10 mg of liraglutide filled into an enteric-coated capsule (Evonik Nutrition and Health, Darmstadt, Germany).
Blood samples were taken into heparinized tubes (0.8 ml) before administration and at 0.5, 1, 2, 4, 8 and 24 h
after intravenous injection as well as 0.5, 1, 2, 3, 4, 8 and 24 h after oral administration, immediately centrifuged
at 3000 × g for 10 min and the plasma was stored at -80◦C until analysis.
The second study was performed at LPT Laboratory of Pharmacology and Toxicology GmbH & Co KG
(Hamburg, Germany) under the German authorization number 33.2-42502-05-LG-01/2014/04 SA, approved by
the Niedersa¨chsisches Landesamt fu¨r Verbraucherschutz und Lebensmittelsicherheit, Oldenburg, Germany. Two
animals received 0.8 mg liraglutide as nasal administration comprising of two spray puffs (one spray puff of 0.1 ml
per nostril) of a 4 mg/ml liraglutide solution in PBS followed after a wash-out of 1 week by oral administration of
5 ml of a 2 mg/ml solution of liraglutide in PBS. Blood samples were drawn into heparinized tubes (0.8 ml) before
and at 0.5, 1, 2, 3, 4, 6, 10 and 24 h after administration, immediately centrifuged at 20,000 × g for 2 min and
the plasma was stored at -20◦C until analysis.
Drugs, chemicals, solvents & materials
GMP-grade liraglutide was purchased from ChemWerth, Inc. (CT, USA). Isotopically labeled internal standard
(IS) (13C6,15N)-Leu(26)-liraglutide was purchased from Peptide Specialty Laboratories GmbH (PSL; Heidelberg,
Germany). Remaining reagents and solvents (water, methanol [MeOH], acetonitrile [ACN] and formic acid [FA])
used for sample preparation, chromatography and MS were of the highest analytical quality (ULC/MS grade)
and were purchased from Biosolve (Valkenswaard, The Netherlands). Blank beagle plasma for calibration, quality
control (QC) and validation purposes was purchased from Innovative Research (MI, USA).
Standard solutions
For preparing calibration and QC stock solutions, liraglutide was independently weighed into low-bind reaction
tubes and subsequently dissolved in 1 ml of PBS because of increased solubility and to avoid adsorption loss
observed for glass vessels. Solutions were diluted 100-fold with ACN/water (1/1, v/v) + 0.1% FA. Polypropylene
tubes were used as vessels to prevent adsorption. A series of calibration subsolutions at concentrations of 0.1, 0.4,
1, 3, 10, 30, 100 and 200 ng/ml were prepared by diluting the stock solution with ACN/water (1/1, v/v) + 0.1%
FA. QC subsolutions were prepared at the LLOQ (0.1 ng/ml) and at 0.275 (QC A), 5.5 (QC B), 110 (QC C) and
1000 ng/ml (dilution QC D).
The IS solution ([13C6,15N]-Leu(26)-liraglutide; 90 ng/ml) was prepared accordingly. Solutions were kept at
4◦C. Stability of the solutions was proven for 3 month by quantification of 3-month-old QC solutions with freshly
prepared calibration solutions.
Plasma sample preparation
Calibration and QC plasma samples (100 μl) were spiked with 25 μl of IS spike solution and 25 μl of the respective
calibration orQC spike solution in 2ml reaction tubes. DilutionQC samples were spiked with 25μl QCD solution
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Table 1. Optimized parameters for the detection of liraglutide using UPLC–MS/MS with positive heated electrospray
ionization and multiple reaction monitoring.
MS parameter Liraglutide [13C6,15N]-Leu(26)-liraglutide
Spray voltage 2800 V 2800 V
Cone voltage 50 V 50 V
Source temperature 150◦C 150◦C
Desolvation gas flow (N2) 1000 l/h 1000 l/h
Desolvation temperature 600◦C 600◦C
MRM transition (m/z) 938.8 → 1064.1 940.5 → 1067.6
Dwell time 160 ms 160 ms
Collision energy 22 V 22 V
Collision gas flow (Ar) 0.15 ml/min 0.15 ml/min
MRM: Multiple reaction monitoring.
and subsequently 12.5 μl added to 90 μl blank plasma. Then 22.5 μl ACN/water (1/19 + 0.1% FA, v/v) for
volume substitution was added as well as 25 μl IS. Study plasma samples (100 μl) were also spiked with 25 μl of IS
and 25 μl of ACN/water (1/19 + 0.1% FA, v/v) for volume substitution. Subsequently, protein precipitation was
performed on Impact R© protein precipitation plates (Phenomenex, CA, USA) by addition of the plasma samples to
the wells containing 300 μl of MeOH. The plate was sealed, shaken for 1 min and positive pressure applied (15 psi;
positive pressure unit, Waters, MA, USA) to transfer protein-depleted extracts to a 2 ml 96-well collection plate
(Eppendorf, Hamburg, Germany). To each well 350 μl of 10% aqueous ammonia was added and gently mixed.
750 μl of the samples were subsequently transferred to an anion exchange Oasis R© MAX μ-elution plate (Waters)
that was operated with positive pressure. Wells were washed with 5% ammonia in 1/1 MeOH/water followed by
20% aqueous ACN containing 0.05% FA. Elution of the samples into a 96-well collection plate (800 μl; Waters)
was performed with two times 30 μl of 5% FA in 1/1 ACN/water. The collection plates were sealed and transferred
into the Sample Manager for direct injection onto the UPLC–MS/MS system.
Instrumental analysis parameters
A Waters Xevo TQ-S with Z-spray ionization and step wave source optimization equipped with an Acquity I-class
UPLC R© system consisting of a Waters Sample Manager flow-through-needle (FTN) and Binary Solvent Manager
including cooled sample trays, integrated column heater and degasser was utilized for analysis.
A Waters Acquity BEH C18 column (1.7 μm, 2.1 × 50 mm) with integrated filter disc heated to 40◦C was
employed for UPLC separation. An injection volume of 20 μl was utilized. Two eluents were used: eluent A
consisting of 5% aqueous ACN with 0.1% (v) FA, and eluent B consisting of ACN containing 0.1% FA volume
(v). The flow rate was 0.5 ml/min and was completely introduced in ion source. Chromatographic separation
was achieved with a gradient starting at 80% A/20% B for 0.1 min, followed by a change of the eluent ratio
to 5% A/95% B within 2.4 min (0.1–2.5 min). This ratio was then held for an additional 0.5 min. To reduce
carry-over the ratio of the eluents was subsequently changed to 95% A/5% B within the next 0.5 min, followed by
a change to 5% A/95% B within 0.5 min. The system was finally reset to starting conditions within the following
0.5 min. Equilibration of the UPLC system with the starting eluent ratio was performed for 1 min in which the
Sample Manager set up the subsequent injection. This leads to a total cycle time of 5.5 min.
Z-spray ionization parameters weremanually optimized and theXevoTQ-Swas tuned automatically to liraglutide
and the IS usingMassLynx V4.1 system software (Waters) and the integrated IntelliStart standard procedures.MRM
measurements were performed using argon as collision gas for CID with MS/MS transitions monitored in the
positive ion mode. Mass spectrometric parameters are shown in Table 1.
Validation of the analytical methods
The assay was validated according to the guidelines of the FDA and EMA on bioanalytical method validation [10,11].
Accordingly, accuracy was determined in percent of the nominal value of the ratio of the mean concentrations
measured in individual batches. Likewise, precision was calculated as percent of the determined standard deviation
of the mean measured concentration.
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Validation was performed by the determination of three validation batches with each batch containing at least
eight calibration samples and at least 24 QC samples at different concentrations (LLOQ, QC A, QC B and QC C,
as well as additional dilution QC D; sixfold each). For proving the selectivity of the method blank plasma samples
from six individual beagle dogs were measured and evaluated for interfering signals especially at the retention time
of the analyte. Extraction recovery rates from plasma were determined from the peak areas of QC samples A, B and
C compared with the respective peak areas obtained from blank plasma which was spiked with the corresponding
amount of analyte after the extraction procedure. Matrix effects of plasma components potentially affecting the
analysis were investigated by comparison of peak areas of blank plasma samples spiked after extraction at QC
levels A, B and C with the respective peak areas of matrix-free UPLC solvent samples spiked with the identical
amount [12].
Short-term and long-term stability of liraglutide in plasma at room temperature and -80◦C was not tested
within this study because it has already been shown for the nanogram per milliliter range [7]. However, the stability
of liraglutide in the nanogram per milliliter range was assessed for plasma samples at -25◦C as well as in three
freeze-and-thaw cycles using QC samples A, B and C. Stability of the extracts in the autosampler was evaluated by
repeated analysis of a 96-well plate after remaining in the autosampler at 10◦C for 24 h.
Calculations & statistical methods
Calibration curves were determined by the ratio of the peak areas of the calibration samples analyteMRM transitions
by the peak area of the IS MRM transition using weighted linear regression (1/x2) with Waters TargetLynx V4.1
software. Pharmacokinetic parameters were calculated with ThermoKinetica Version 5.0 (Thermo Fisher Scientific,
MA, USA) was applied for the calculation of pharmacokinetic parameters. Microsoft Office Excel 2010 (CA, USA)
was used for the calculation of standard deviation, mean concentration and percent of nominal value.
Results & discussion
Choice of the LC–MS/MS system
Because of the requirement of high sensitivity the development of the quantification assay was first performed
on a microflow UPLC–MS/MS system (Acquity M-Class UPLC R© system connected to a Xevo TQ-S equipped
with an ionKey R© inlet system; Waters). A BEH C18 (130 A˚) and BEH C4 (300 A˚) ionKey were tested for the
chromatography of liraglutide. Although sharp peaks with a width at baseline of 4 s could be obtained, liraglutide
showed such substantial carryover that specific analysis in reasonable time was impeded. Therefore, we decided
to switch to UPLC and FTN injection to allow for rigorous washing of the LC-system, which was identified as
the source of carry-over. The observed, extensive carry-over is thought to arise from the acylation with stearic acid
present in liraglutide leading to elevated adsorption.
Performance of the laboratory methods
Mass spectrometric & chromatographic characteristics
Positive electrospray ionization of liraglutide showed themaximum intensity for the (M+4H)4+ signal atm/z 938.8,
which was also observed for the IS at m/z 940.5. Figure 1 shows the respective daughter ion mass spectra and
fragmentation reactions of the (M+4H)4+ signal of liraglutide at 22 V. The most intense CID fragments were
observed at high collision energy (80 V) and at low m/z values. These correspond to immonium ions of single
amino acid residues with the most intense observed at m/z 110.2 which corresponds to the immonium ion of
the N-terminal histidine. Because high interference and background is more common for immonium ions due
to their high abundance in interfering peptides also highly specific large fragments were investigated. The most
intense larger fragment was observed at lower collision energies (22 V) at m/z 1064.1, which showed over a
magnitude lower intensity than the most abundant immonium ions. Because the very high matrix interference
for the immonium ion transitions such as the m/z 938.8 → m/z 110.2 transition impeded sensitive analysis
(S/N ratio <1 at 0.2 ng/ml), we chose the m/z 938.8 → m/z 1064.1 transition for detection in the MRM
which showed more than 40-fold better S/N values (S/N ratio of 40 at 0.2 ng/ml; Figure 2). The m/z 1064.1
fragment constitutes the doubly charged C-terminal fragment after cleavage of the peptide bond between positions
15 and 16 (y16-fragment, Figure 1) which was confirmed with high-resolution mass spectrometry using a Waters
Xevo G2-XS QTof: The found monoisotopic m/z 1063.6282 deviated less than 0.2 p.p.m. from the calculated
monoisotopicm/z 1063.6284 of the y16-fragment. For the isotopically labeled IS, the correspondingmass transition
at m/z 940.5 → m/z 1067.6 was monitored. The mass shift of 3.5 Da of the m/z 1067.6 fragment of the IS in
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Figure 1. Positive product spectrum of liraglutide using collision-induced decomposition at 22 V. The grey bar in the liraglutide structure
depicts the m/z 938.8 → m/z 1064.1. The positions of the isotopic labels in the corresponding internal standard are tagged with stars.
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Figure 2. Quantification of a plasma sample containing 0.2 ng/ml liraglutide. (A) Monitoring of the m/z 938.8 → m/z 110.2 transition
and (B) monitoring of the m/z 938.8 → m/z 1064.1 transition.
comparison to the m/z 1064.1 fragment of the analyte is in line with the doubly charged y16-fragment comprising
the isotopically labeled (13C6,15N)-leucine (Figure 1).
UPLC was performed on a Waters BEH C18 UPLC R© column with a gradient from 80 to 5% aqueous eluent
and a parallel increase of the ACN eluent from 20 to 95% resulting in a fast separation of only 2 min and a peak
width at baseline of 6 s. Well resolved single mass traces were achieved with dwell times of 160 ms for each transition
yielding 20 analysis points per peak (Figure 3). Initially, considerable carryover was observed for liraglutide, which
could be reduced to levels not affecting the analysis by keeping the ACN eluent at 95% for 0.5 min after the
separation gradient and the subsequent run of an additional cleaning gradient. For this cleaning gradient the ACN
fraction was reduced to 5% in 0.5 min followed by an increase to 95% in 0.5 min and subsequently returned to
starting conditions of 20% ACN within 0.5 min. Equilibration of starting conditions was performed for 1 min
while the Sample Manager prepared the following injection which resulted in a total cycle time of 5.5 min.
Extraction by protein precipitation
Isolation of liraglutide was achieved by protein precipitation with a three-time excess of MeOH over plasma,
followed by solid phase extraction (SPE) using mixed mode strong anion exchange and reverse phase sorbent.
MeOHwas used for protein depletion because it showed substantially higher recoveries when compared with ACN.
To enable enrichment of liraglutide in the extracts, anion exchange purification was performed on a μ-elution plate
allowing elution with volumes as little as two times 30 μl. Endogenous components interfered substantially in
analyses of protein precipitation extracts of liraglutide while anion exchange purification efficiently removed matrix
interference likely because of the optimized rigorous washing steps. 5% ammonia in 1/1 MeOH/water removed
basic compounds as well as substances with significant retention on the reverse phase. The following washing step
with slightly acidic 20% aqueous ACN aimed at removing slightly acidic substances while elution of liraglutide was
avoided. Because of these optimized washing steps, matrix interference in the analysis of liraglutide was significantly
reduced.
Plasma recovery rates for the isolation procedure were assessed in triplicate determination at QC levels A, B and C
as well as for IS. Recoveries of IS and QC samples after solely performed protein precipitation ranged between 53.9
and 64.5% while additional anion exchange extraction reduced recoveries to 36.3–39.0%. Remaining components
of biological matrix such as peptides and lipids may influence baseline stability of the chromatography and/or
induce unexpected peaks, and may alter the ionization process by ion suppression/enhancement, which can result
in decreased accuracy and precision particularly at low concentrations [12]. The more efficient separation of matrix
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Figure 3. Selected UPLC–MS/MS chromatograms of processed plasma samples with liraglutide transition (left) and internal standard
transition (right). (A) Blank plasma sample, (B) plasma sample with added IS, (C) plasma sample at LLOQ concentration (representing
0.1 ng/ml, (D) plasma sample at QC B concentration (representing 5.5 ng/ml) and (E) plasma sample of beagle dog number 5, 6 h after
nasal administration of 0.8 mg liraglutide (quantified liraglutide concentration 0.13 ng/ml).
IS: Internal standard; QC: Quality control.
with optimized anion exchange extraction improved the matrix effect to ranges between -20.4 and -31.2% as
compared with protein-depleted extracts, which showed matrix effects of -30.0 to -41.7%. Taking into account
the enrichment of liraglutide in the extracts by the μ-elution SPE procedure, the amount of liraglutide injected
onto the UPLC–MS/MS system is larger after SPE. Because of the enrichment by the SPE procedure the assay
holds the perspective for lowering the LLOQ when using larger amounts of plasma. Additionally, the S/N ratio
was maximized by the anion exchange extraction procedure because of significantly reduced matrix interference.
Analysis of QC B samples of lipemic and hemolytic plasma revealed no influence on sample analysis with respective
accuracies of 93.0 and 89.5%. Although lipemic QC plasma samples showed peak areas similar to normal plasma,
hemolytic plasma yielded substantially lower peak areas. This may either be attributed to decreased recovery or an
increased matrix effect. Therefore, analysis of hemolytic plasma samples at low concentrations should be avoided.
Validation results
The isolation by protein precipitation followed by anion exchange extraction combined with UPLC–MS/MS
quantification entirely met FDA’s and EMA’s requirements for bioanalytical method validation [10,11]. The absence
of interfering signals in blank matrices from six different beagle dogs confirmed the selectivity of the assay. Figure 3
shows typical chromatograms of blank plasma as well as plasma samples spiked with IS, at LLOQ, at QC B, and
beagle plasma 6 h after nasal administration of 0.8 mg liraglutide. Correlation coefficients (r2) of ≥0.998 (linear
regression and 1/x2 weighting) were achieved within the calibrated range (0.1–200 ng/ml). The dynamic range
of the assay optimally covers the therapeutic range of liraglutide in humans and matches the performance of the
previously described immunoassay for pharmacokinetic analysis (0.068–16.9 ng/ml) [13]. Within-batch accuracies
(QC A–C) varied between 93.8 and 105.4% and the batch-to-batch accuracies ranged from 96.7 to 101.4%
showing precision values of <6.2%. Accuracy at LLOQ level varied between 92.8 and 106.3% within-batch
and was 98.7% batch-to-batch with corresponding precision values of <10.7%. Accuracy and precision values are
shown in Table 2. This precise intra- and interday quantification is attributed to the quantification using isotopically
labeled IS that completely accounts for matrix effects and recovery.
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Table 2. Summary of quality control results for liraglutide in plasma.
Quality control criteria LLOQ (0.100 ng/ml) QC A (0.275 ng/ml) QC B (5.50 ng/ml) QC C (110 ng/ml)
Within batch
1 Mean (ng/ml) 0.093 0.267 5.39 112
Accuracy (%) 92.8 96.9 98.0 101.8
Precision (%CV) 7.57 3.26 3.52 4.26
2 Mean (ng/ml) 0.097 0.290 5.40 112
Accuracy (%) 96.8 105.4 98.1 101.7
Precision (%CV) 10.7 3.69 2.64 2.14
3 Mean (ng/ml) 0.106 0.260 5.16 111
Accuracy (%) 106.3 94.5 93.8 100.8
Precision (%CV) 8.38 5.18 1.18 1.69
Batch-to-batch
Mean (ng/ml) 0.099 0.272 5.32 112
Accuracy (%) 98.7 98.9 96.7 101.4
Precision (%CV) 10.3 6.20 3.28 2.78
N = 6 replicates at LLOQ and each QC concentration.
CV: Coefficient of variation; QC: Quality control.
For quantification of intravenously administered liraglutide, a tenfold dilution with blank plasma (QC D) was
validated using 10 μl of plasma. Accuracy of the dilution QC D was 106.9%, hence the assay can be applied to
quantify liraglutide in plasma in a range of 0.1–2000 ng/ml. Additionally, the incurred sample reanalysis of 25
beagle samples met FDA’s and EMA’s requirements with 84% of the samples showing a deviation of <20%.
Stability
Stability in the nanogram per milliliter range was tested within our validation procedure using three freeze-and-thaw
cycles and samples stored at -25◦C for 2 month for QC A, B and C plasma samples. Accuracies of the freeze-and-
thaw samples ranged between 103.3 and 110.4%, confirming the stability of liraglutide during the freeze-and-thaw
cycles. Further, QC A, B and C samples stored at -25◦C for 2 months showed accuracies ranging from 108.9 to
110.4%. Liraglutide is, therefore, considered stable in plasma for at least 2 months at -25◦C. Stability in plasma
has previously been demonstrated for 1 week at -80◦C and 4 h at room temperature for the nanogram per milliliter
range [7]. Additionally, plasma extracts were stable after remaining in the Sampler Manager for 24 h. The stability
of liraglutide in the stock and standard solutions was confirmed by the quantification of a freshly prepared stock
solution after 3 month. The prepared QC A, B and C samples of this fresh stock solution showed accuracies ranging
from 105.1 to 113.1%.
Pharmacokinetics of liraglutide after nasal, oral & intravenous administration to beagle dogs
Because of the acylation with palmitic acid, liraglutide exhibits a relatively long half-life of 8 h in humans after
intravenous injection [14]. The half-life determined in beagle dogs after intravenous injection was quite similar with
9.4 h and comparable after oral administration with 8.4 h. The volume of distribution after intravenous and oral
administration of 0.057 l/kg and 0.070 l/kg, respectively, was also comparable to the reported values in humans of
0.07 l/kg [14]. This similarity in the pharmacokinetic characteristics is most likely because of the extensive protein
binding of liraglutide of>98% [15] in both species. Pharmacokinetic characteristics in beagle dogs after intravenous,
nasal and oral administration are shown in Table 3.
The oral bioavailability of liraglutide when administered in solution was determined as 0.006%. After oral
administration of 10 mg liraglutide in enteric-coated capsules for protection from proteolysis in the stomach, no
detectable plasma concentrations were observed. This indicates an absolute bioavailability of less than 0.001%
which was estimated to represent the minimum detectable Cmax value when assuming a similar pharmacokinetic
profile as observed for oral liraglutide in solution. This may be attributed to a delayed release of liraglutide from
the enteric-coated capsule or a solubility issue of the solid liraglutide.
Nasal administration of 0.8 mg liraglutide resulted in detectable plasma concentrations of up to 0.13 ng/ml.
Nasal absorption appeared very slow with Cmax values reached 6–10 h after administration (Figure 4). Although
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Table 3. Single dose pharmacokinetics of liraglutide in beagle dogs after intravenous bolus injection and after
oral administration in solution.
Liraglutide dose and route
of administration
Dog number T1/2 (h) Cmax (ng/ml) AUCInf (h ×
ng/ml)
F (%) VZ (l/kg) Cl (ml/min)
Intravenous 0.5 mg 1 9.15 984 10330 100 0.048 0.81
2 9.37 915 8515 100 0.059 0.98
3 10.4 944 11785 100 0.060 0.71
4 8.83 823 8594 100 0.060 0.97
Nasal 0.8 mg 5 35.0 0.13 6.13 0.039 0.17 0.66
6 19.3 0.12 3.42 0.022 0.17 1.19
Oral 10 mg 7 8.90 1.26 19.2 0.010 0.071 0.65
8 10.5 0.25 4.07 0.002 0.070 0.77
AUCInf: Area under the plasma concentration-time curve extrapolated to infinity; Cl: Clearance corrected for absolute bioavailability; Cmax: Maximal plasma concentration; F:
Absolute bioavailability; T1/2: Half-life; VZ: Volume of distribution corrected for absolute bioavailability.
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Figure 4. Plasma concentration-time profiles of liraglutide after intravenous, nasal and oral administration in
solution. The upper curves represent the single intravenous bolus injection of 0.5 mg liraglutide to beagle dogs
number 1–4. The middle curves correspond to oral administration of 10 mg liraglutide to beagle dogs numbers 5 and
6. The lower curves represent the nasal administration of 0.8 mg liraglutide to beagle dogs numbers 7 and 8.
clearance was comparable regardless of the route of administration, the half-life after nasal administration of
liraglutide was prolonged in comparison to oral and intravenous administration with approximately 27 h and the
volume of distribution was also substantially larger with 0.17 l/kg which both is attributed to the slow absorption
from the nasal cavity. The nasal bioavailability was calculated as 0.03%. Minimal oral and nasal bioavailability
is not uncommon for peptides because of their instability against proteolytic digestion and poor membrane
penetration [16].
Conclusion
Only few assays for the quantification of liraglutide in plasma using LC–MS/MS have been described with the
most sensitive having an LLOQ of 0.5 ng/ml when using 50 μl of plasma. None of these assays used an isotopically
labeled IS. In this paper, we describe a novel ultrasensitive UPLC–MS/MS assay with an LLOQ of 0.1 ng/ml
(27 picomol/l) when using a plasma volume of 100 μl. This is the most sensitive assay to date and also the first
utilizing an isotopically labeled IS which resulted in excellent accuracy (<3.3% batch-to-batch). The improvement
in sensitivity could be achieved by enrichment of liraglutide in plasma extracts while concurrentlyminimizingmatrix
interference because of an optimized SPE procedure. The utilization of μ-elution SPE in 96-well format for sample
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extraction allowed rigorous washing which efficiently minimized matrix interference and enabled enrichment of
liraglutide in the extracts by elution in small volumes. This sample enrichment also holds the possibility of lowering
the LLOQ when using larger amounts of plasma. Further, combination of UPLC with a sensitive MS/MS enabled
high sensitivity in MRM while optimized chromatographic conditions facilitated short chromatograms (2 min)
with sharp peaks to further maximize intensity and S/N ratio as well as separating interfering signals. The assay
was successfully applied to plasma samples of beagle dogs that received liraglutide by nasal, oral and intravenous
administration allowing the determination of the corresponding bioavailabilities.
Future perspective
Bioanalysis of peptides is increasingly performed by LC–MS/MS replacing the traditionally performed highly
sensitive immunoassays. LC–MS/MS is usually faster in the development and shows superior dynamic range and
selectivity. The here described assay using readily available equipment, matching the performance in sensitivity
of the previously applied immunoassay, is a step toward routine bioanalysis of peptides with high potency and,
therefore, low plasma concentrations by ultrasensitive LC–MS/MS methodologies.
Summary points
Aim
• GLP-1 analogs including the therapeutic peptide liraglutide are increasingly utilized and recommended early in
the treatment of Type 2 diabetes mellitus. Like most peptides liraglutide needs to be administered by injection.
• To support future development of alternative routes of administration an ultrasensitive UPLC–MS/MS assay for
the quantification of liraglutide in plasma is required. The ultrasensitive bioanalysis of liraglutide by MS/MS is
challenging because of its high molecular weight which leads to signal dilution in collision induced
decomposition.
Results & discussion
• An ultrasensitive UPLC–MS/MS assay using multiple reaction monitoring and positive electrospray ionization was
developed entirely complying with US FDA’s and EMA’s guidelines on bioanalytical method validation.
• Because of substantial adsorption characteristics of liraglutide its bioanalysis on a microflow UPLC was impeded
and was therefore performed on a UPLC with flow-through-needle injection allowing for rigorous washing which
reduced carryover to levels not affecting the assay’s specificity.
• Extraction of liraglutide from plasma was achieved by combining protein precipitation and solid-phase
extraction. This efficiently removed endogenous interference because of rigorous washing steps while it
concentrated the samples through μ-elution.
• This assay has the lowest reported LLOQ of 0.1 ng/ml (when using 100 μl of plasma) matching the performance
of the previously described immunoassay and optimally covers the therapeutic range of liraglutide. It is the first
assay for the quantification of liraglutide utilizing an isotopically labeled internal standard which resulted in
precise analysis showing excellent interday accuracy.
• This assay was applied for the determination of liraglutide pharmacokinetics and bioavailability after
intravenous, nasal and oral administration to beagle dogs. Absolute bioavailability of liraglutide after oral and
nasal administration was 0.006 and 0.03%, respectively.
Conclusion
• To our knowledge, this is the most sensitive assay for the quantification of liraglutide using MS/MS also showing
excellent accuracy and precision and was successfully applied to a pharmacokinetic study in beagle dogs.
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